全文获取类型
收费全文 | 3407篇 |
免费 | 253篇 |
国内免费 | 19篇 |
专业分类
耳鼻咽喉 | 17篇 |
儿科学 | 36篇 |
妇产科学 | 53篇 |
基础医学 | 420篇 |
口腔科学 | 318篇 |
临床医学 | 324篇 |
内科学 | 901篇 |
皮肤病学 | 71篇 |
神经病学 | 179篇 |
特种医学 | 115篇 |
外科学 | 543篇 |
综合类 | 15篇 |
预防医学 | 227篇 |
眼科学 | 15篇 |
药学 | 166篇 |
中国医学 | 12篇 |
肿瘤学 | 267篇 |
出版年
2023年 | 27篇 |
2022年 | 44篇 |
2021年 | 124篇 |
2020年 | 85篇 |
2019年 | 90篇 |
2018年 | 114篇 |
2017年 | 89篇 |
2016年 | 95篇 |
2015年 | 124篇 |
2014年 | 141篇 |
2013年 | 169篇 |
2012年 | 277篇 |
2011年 | 246篇 |
2010年 | 159篇 |
2009年 | 173篇 |
2008年 | 234篇 |
2007年 | 197篇 |
2006年 | 200篇 |
2005年 | 203篇 |
2004年 | 205篇 |
2003年 | 163篇 |
2002年 | 154篇 |
2001年 | 27篇 |
2000年 | 19篇 |
1999年 | 31篇 |
1998年 | 29篇 |
1997年 | 24篇 |
1996年 | 15篇 |
1995年 | 14篇 |
1994年 | 11篇 |
1993年 | 9篇 |
1992年 | 17篇 |
1991年 | 15篇 |
1990年 | 17篇 |
1989年 | 17篇 |
1988年 | 13篇 |
1987年 | 11篇 |
1986年 | 8篇 |
1985年 | 5篇 |
1984年 | 12篇 |
1983年 | 7篇 |
1982年 | 7篇 |
1980年 | 14篇 |
1979年 | 6篇 |
1978年 | 5篇 |
1977年 | 7篇 |
1971年 | 2篇 |
1970年 | 2篇 |
1969年 | 4篇 |
1966年 | 2篇 |
排序方式: 共有3679条查询结果,搜索用时 203 毫秒
101.
102.
Antibodies to ribosomal P proteins of Trypanosoma cruzi in Chagas disease possess functional autoreactivity with heart tissue and differ from anti-P autoantibodies in lupus
下载免费PDF全文
![点击此处可从《Proceedings of the National Academy of Sciences of the United States of America》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Dan Kaplan Ines Ferrari Pablo Lopez Bergami Evelina Mahler Gabriela Levitus Pablo Chiale Johan Hoebeke Marc H. V. Van Regenmortel Mariano J. Levin 《Proceedings of the National Academy of Sciences of the United States of America》1997,94(19):10301-10306
Anti-P antibodies present in sera from patients with chronic Chagas heart disease (cChHD) recognize peptide R13, EEEDDDMGFGLFD, which encompasses the C-terminal region of the Trypanosoma cruzi ribosomal P1 and P2 proteins. This peptide shares homology with the C-terminal region (peptide H13 EESDDDMGFGLFD) of the human ribosomal P proteins, which is in turn the target of anti-P autoantibodies in systemic lupus erythematosus (SLE), and with the acidic epitope, AESDE, of the second extracellular loop of the β1-adrenergic receptor. Anti-P antibodies from chagasic patients showed a marked preference for recombinant parasite ribosomal P proteins and peptides, whereas anti-P autoantibodies from SLE reacted with human and parasite ribosomal P proteins and peptides to the same extent. A semi-quantitative estimation of the binding of cChHD anti-P antibodies to R13 and H13 using biosensor technology indicated that the average affinity constant was about 5 times higher for R13 than for H13. Competitive enzyme immunoassays demonstrated that cChHD anti-P antibodies bind to the acidic portions of peptide H13, as well as to peptide H26R, encompassing the second extracellular loop of the β1 adrenoreceptor. Anti-P antibodies isolated from cChHD patients exert a positive chronotropic effect in vitro on cardiomyocytes from neonatal rats, which resembles closely that of anti-β1 receptor antibodies isolated from the same patient. In contrast, SLE anti-P autoantibodies have no functional effect. Our results suggest that the adrenergic-stimulating activity of anti-P antibodies may be implicated in the induction of functional myocardial impairments observed in cChHD. 相似文献
103.
Victor Alfonso Jimenez Diaz Antonio Tello-Montoliu Raul Moreno Ignacio Cruz Gonzalez Jose Antonio Baz Alonso Rafael Romaguera Eduardo Molina Navarro Pablo Juan Salvadores Emilio Paredes Galan Antonio De Miguel Castro Guillermo Bastos Fernandez Alberto Ortiz Saez Saleta Fernandez Barbeira Sergio Raposeiras Roubin Juan Ocampo Miguez Antonio Serra Peñaranda Mariano Valdes Chavarri Angel Cequier Fillat Andres Iñiguez Romo 《JACC: Cardiovascular Interventions》2019,12(1):22-32
Objectives
The REAC-TAVI (Assessment of platelet REACtivity after Transcatheter Aortic Valve Implantation) trial enrolled patients with aortic stenosis (AS) undergoing transcatheter aortic valve replacement (TAVR) pre-treated with aspirin + clopidogrel, aimed to compare the efficacy of clopidogrel and ticagrelor in suppressing high platelet reactivity (HPR) after TAVI.Background
Current recommendations support short-term use of aspirin + clopidogrel for patients with severe AS undergoing TAVR despite the lack of compelling evidence.Methods
This was a prospective, randomized, multicenter investigation. Platelet reactivity was measured at 6 different time points with the VerifyNow assay (Accriva Diagnostics, San Diego, California). HPR was defined as (P2Y12 reaction units (PRU) ≥208. Patients with HPR before TAVR were randomized to either aspirin + ticagrelor or aspirin + clopidogrel for 3 months. Patients without HPR continued with aspirin + clopidogrel (registry cohort). The primary endpoint was non-HPR status (PRU <208) in ≥70% of patients treated with ticagrelor at 90 days post-TAVR.Results
A total of 68 patients were included. Of these, 48 (71%) had HPR (PRU 273 ± 09) and were randomized to aspirin + ticagrelor (n = 24, PRU 277 ± 08) or continued with aspirin + clopidogrel (n = 24, PRU 269 ± 49). The remaining 20 patients (29%) without HPR (PRU 133 ± 12) were included in the registry. Overall, platelet reactivity across all the study time points after TAVR was lower in patients randomized to ticagrelor compared with those treated with clopidogrel, including those enrolled in the registry (p < 0.001). The primary endpoint was achieved in 100% of patients with ticagrelor compared with 21% with clopidogrel (p < 0.001). Interestingly, 33% of clopidogrel responder patients at baseline developed HPR status during the first month after TAVR.Conclusions
HPR to clopidogrel is present in a considerable number of patients with AS undergoing TAVR. Ticagrelor achieves a better and faster effect, providing sustained suppression of HPR to these patients. (Platelet Reactivity After TAVI: A Multicenter Pilot Study [REAC-TAVI]; NCT02224066) 相似文献104.
Jorge A. Belardi MD FACC FSCAI Mariano Albertal MD PHD FACC 《Catheterization and cardiovascular interventions》2016,87(3):532-533
- Acute kidney injury (AKI) is frequently observed immediately after transcatheter aortic valve implantation (TAVI).
- Both classifications, the RIFLE (the Risk, Injury, Failure, Loss, and End‐stage Kidney) and the KDIGO (Kidney Disease: Improving Global Outcomes) from the VARC‐2 (Valve Academic Research Consortium‐2) are fairly interchangeable and performed well as clinical predictors of all‐cause mortality.
- Patients with baseline reduced glomerular filtration rate (GFR) or known atherosclerotic arterial disease are at increased risk of AKI.
105.
Abundes A Rivera Jde J Arizmendi E Farell J Ledesma M Montoya S 《Revista espa?ola de cardiología》2002,55(11):1205-1208
BACKGROUND AND OBJECTIVES: We evaluated the technical and clinical results of implantation of the Atlas stent, the hospital stay, and the short and long-term clinical and angiographic outcome. PATIENTS AND METHOD: The study included 169 patients (60.1 10.8 year-old), 60.3% of which had acute coronary syndromes and complex lesions. Immediate success was achieved in 98% of cases. The clinical follow-up in 85.7% of the patients at 14.3 6.8 months, revealed that 89% remained free of adverse events and most (94.4%) were functional class I of the CCS. Angiographic follow-up at 8.4 4.1 months of 40.9% of the cases revealed restenosis in 27.9%. There were 2 cases of subacute thrombosis. CONCLUSIONS: The application of the Atlas stent in patients with a diverse clinical spectrum demonstrated good immediate and long term results, with a rate of restenosis similar to that of other stents available on the market. 相似文献
106.
Ponce de Leon D Acevedo-Vasquez E Alvizuri S Gutierrez C Cucho M Alfaro J Perich R Sanchez-Torres A Pastor C Sanchez-Schwartz C Medina M Gamboa R Ugarte M 《The Journal of rheumatology》2008,35(5):776-781
OBJECTIVE: Tuberculosis (TB) in patients with rheumatoid arthritis (RA) undergoing treatment with anti-tumor necrosis factor (TNF) agents is commonly the result of reactivation of latent TB infection (LTBI); detection and treatment of LTBI is essential before treatment with anti-TNF agents. We reported previously that the tuberculin skin test (TST) is inaccurate for diagnosis of LTBI in patients with RA. Here, we compare the prevalence of LTBI in RA patients and matched controls according to positive TST and QuantiFeron-TB Gold In-Tube version (QFT) results and determine their agreement. METHODS: A cross-sectional study of 101 RA patients and 93 controls was conducted in Lima, Perú, where the prevalence of LTBI in the general population has been estimated to be 68%. Blood was drawn for QFT assay followed by TST using 2-TU of RT 23 purified protein derivative. TST was deemed positive at >or= 5 mm for RA patients and >or= 10 mm for controls. RESULTS: There were no significant differences between RA patients and controls for age, sex, bacillus Calmette-Guérin vaccination, or history of or contact with TB. 88% of patients had active RA disease and 2 (1.9%) patients had indeterminate QFT results. The number of subjects testing positive with the QuantiFeron assay was comparable between patients and controls (44.6% vs 59.1%, respectively), whereas the TST detected significantly less LTBI among RA patients (26.7%) than controls (65.6%). Thus, the rate of LTBI in RA patients represented 75% and 41% of the rate in their controls using QFT or TST, respectively (p = 0.008). Poor agreement between TST and QFT was seen in RA patients, but in controls, good agreement was observed between these tests. CONCLUSION: In a TB-endemic population, the QuantiFeron-TB Gold In-Tube assay seemed to be a more accurate test for detection of LTBI in RA patients compared with the TST, and may potentially improve the targeting of prophylactic therapy before treatment with anti-TNF agents. 相似文献
107.
108.
Evaluation of a Standardized Program for Training Practicing Anesthesiologists in Ultrasound‐Guided Regional Anesthesia Skills
下载免费PDF全文
![点击此处可从《Journal of ultrasound in medicine》网站下载免费的PDF全文](/ch/ext_images/free.gif)
109.
110.
Bruna Souza Felix Bravo Camila Roos Mariano Da Rocha Julien Toni De Bastos Priscila Mara Chaves e Silva 《The Journal of clinical and aesthetic dermatology》2015,8(6):30-35
The periorbital subunit is one of the first facial regions to show signs of aging, primarily due to volume depletion of the soft tissue and bony resorption. Surgical and office-based nonsurgical procedures form an important basis for periorbital rejuvenation. It is important to make a detailed clinical evaluation of the patient to indicate the most appropriate procedure to be performed. With the objective of showing a nonsurgical procedure for the rejuvenation of the periorbital area, the authors describe a technique of applying fillers in the upper and lower periorbital regions, paying attention to the anatomy of this facial region and the type of product to be used besides the expected results of the procedure and its possible adverse effects and complications. The nonsurgical rejuvenation of the periorbicular region with hyaluronic acid is a new and innovative technique. In the opinion of the authors, it is a great aesthetic impact area and consequently brings high satisfaction to patients.Maintaining a youthful and pleasant appearance of the face in today’s culture impacts quality of life in many patients. The facial contour remodeling is being revolutionized by new nonsurgical techniques.Facial aging is a complex and dynamic process. All people age differently as a result of imbalance, disharmony, and disproportion of the aging process between the overlying soft tissue and the underlying bony frameworks.1 The upper periorbital subunit is one of the first facial regions to show signs of aging, and even minor changes in its structure and volume can distort the perceived emotions and health of patients.2 An aesthetic and youthful upper periorbital subunit is characterized by a well-defined brow of appropriate height and shape, fullness of the upper periorbit, a crisp and well-defined upper eyelid crease, minimal skin excess, and good skin quality.3,4In the aging process of this facial area, one group of patients displays signs of aging due predominantly to soft tissue ptosis of the upper eyelid, requiring surgical excision. Another group presents with volume depletion of the soft tissue and bony resorption of the orbit. The loss of septal support, leading to brow prolapse and an exacerbation of upper eyelid fullness and congestion, can also contribute to the aging process. This appearance is characterized by deflation of the upper eyelid as well as hollowing and visibility of the supraorbital bony rim, leading to a sunken, hollow, and skeletonized orbit, which can make the patient appear sickly, anorexic, and old. In recent years, modern facial rejuvenation surgery has evolved toward volume restoration in addition to tissue suspension.2Comprehensive analysis of both soft tissue and bony structural changes are essential for the periorbital rejuvenation. Surgical procedures and office-based nonsurgical procedures form an important basis for periorbital rejuvenation, including cosmeceuticals, chemical peels, laser and light treatments, neurotoxins, and fillers. Improved understanding of the pathophysiology of aging and technical advancements in nonsurgical techniques has enabled us to achieve better and more comprehensive improvement for patients.5 相似文献